Klotho Neurosciences, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph A. Sinkule
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 13576 Walnut Street Omaha NE United States of America 68144
- IPO Date
- Apr 29, 2022
- CIK
- 0001907223
- Website
- klothoneuro.com
- Similar Companies
- Business
- Klotho Neurosciences, Inc. develops innovative gene and cell therapies focused on treating neurodegenerative and age-related disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. The company’s core products include gene therapy candidates KLTO-101 and KLTO-202, with KLTO-202 receiving FDA Orphan Drug Designation for ALS treatment. Klotho's technology platform, licensed exclusively from the Autonomous University of Barcelona, leverages the therapeutic potential of the human α-Klotho gene to address cognitive decline and extend healthy longevity. The company operates globally with a research center in Okinawa, Japan, and engages in partnerships to enhance its manufacturing and development capabilities. Recent major developments include a strategic manufacturing partnership with AAVnerGene to produce its KLTO-202 gene therapy candidate using AAVnerGene’s platform, securing $11 million in financing, and regaining Nasdaq compliance. Klotho also signed a letter of intent to acquire select assets from Turn Biotechnologies, including the Epigenetic Reprogramming of Age (ERA) platform and eTurna RNA delivery system, aimed at expanding therapeutic applications into regenerative medicine for dermatology, ophthalmology, immunology, osteoarthritis, muscle health, and other diseases. This acquisition is anchored by a $300 million global pharma co-development and out-licensing agreement in South Korea. Post-acquisition, Klotho plans to rebrand to reflect its expanded mission beyond neurology, targeting a broader spectrum of age-related diseases such as cardiometabolic conditions, cancer, sarcopenia, and osteoporosis. The company also received recognition for its innovation with the 2025 BioTech Breakthrough Cell Therapy Innovation of the Year Award. Founded in 2019 and headquartered in New York, Klotho Neurosciences operates primarily in the biotechnology industry, focusing on life-extending therapies through protein, cell, and gene interventions targeting high unmet medical needs in aging and neurodegeneration. Its pipeline reflects a comprehensive approach to developing transformative medicines for chronic age-related diseases, with ongoing expansion into complementary anti-aging technologies and therapeutics aimed at improving muscle strength, bone health, and overall longevity indicators.
Klotho Neurosciences (NASDAQ:KLTO) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast
Citius Pharmaceuticals (NASDAQ:CTXR) and Klotho Neurosciences (NASDAQ:KLTO) Head-To-Head Comparison
Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML
Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026
KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR
Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)
Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence
Klotho Neurosciences to Present at the Biotech Showcase 2026
Klotho Neurosciences (NASDAQ:KLTO) Trading Up 0.6% – What’s Next?
Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston
Klotho Neurosciences Announces Expiration of Letter of Intent
Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology
UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules
Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation